Literature DB >> 3629206

Hepatotoxicity associated with low-dose, long-term methotrexate treatment of rheumatoid arthritis.

E Szanto, B Sandstedt, B Kollberg.   

Abstract

Liver biopsies were performed in 17 patients with therapy-refractory rheumatoid arthritis who were treated successfully with 5-15 mg/week methotrexate (mtx). The average duration of exposure to mtx therapy for each patient was 2.8 years (range 1.5-5 years). Total cumulative mtx doses ranged between 633 and 1,655 mg (mean 1,060 mg). The biopsies revealed 16 cases of normal histology, of which 3 showed nuclear variability in the hepatocytes; 4 with mild fatty infiltration, 2 with mild fatty infiltration and portal round cell infiltration. Portal fibrosis was found in one patient who had psoriasis in addition to clinical RA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3629206     DOI: 10.3109/03009748709102922

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  2 in total

Review 1.  Methotrexate in rheumatoid arthritis: can current knowledge and experience justify its use as a first-line disease-modifying agent?

Authors:  S Tariq; S M Tariq
Journal:  Postgrad Med J       Date:  1993-10       Impact factor: 2.401

2.  Low-dose methotrexate treatment of rheumatoid arthritis; long-term observation of efficacy and safety.

Authors:  E Szanto
Journal:  Clin Rheumatol       Date:  1989-09       Impact factor: 2.980

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.